Introduction {#Sec1}
============

Immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is a rare monogenic primary immunodeficiency caused by mutations in forkhead box protein 3 (*FOXP3*) gene. In 1982, Powell et al.^[@CR1]^ reported a large kindred with 19 affected males across 5 generations presenting diarrhoea, which was lethal in most infants in early childhood. In 2001, Chatila et al.^[@CR2]^ identified mutations in *FOXP3* \[initially called *JM2* in the centromeric region of the X chromosome (Xq11.3-q13.3)\] in two unrelated families with IPEX phenotype. In mice, the so-called "scurfy mutation" which arose spontaneously in *Foxp3* and triggered a lymphoproliferative disease with multiorgan inflammation, has corroborated the causative role of FOXP3 in driving the disease^[@CR3]^. The *FOXP3* gene is highly conserved across mammals and encodes a key transcription factor required for regulatory T cells (Tregs) development, maintenance and function^[@CR4]^.

To date, approximately 150 patients carrying mutations in *FOXP3* gene have been reported. Classically, IPEX patients present multiorgan autoimmunity, including severe enteropathy, type 1 diabetes (T1D) and dermatitis. Outcome of patients is generally poor, unless successful hematopoietic stem cell transplantation (HSCT) can be proposed.

In the present retrospective multicentre French study of patients carrying *FOXP3* mutations, we aim to highlight the broad spectrum of symptoms in order to facilitate diagnosis as well as clinical management of this rare disease.

Patients and Methods {#Sec2}
====================

Patients {#Sec3}
--------

This multicentre retrospective study reviewed all IPEX patients treated at four French university hospitals between 1980 and 2015 (Necker-Enfants Malades Hospital---Paris, Lyon, Clermont-Ferrand and Bordeaux). Only patients with a documented mutation in the *FOXP3* gene were included. Recorded data comprised: age at onset, clinical symptoms (enteropathy, skin disease, endocrinopathy and allergy) and biological parameters (total IgE, autoimmune enteropathy-related---AIE75 kDa autoantibodies), endoscopic and histopathologic presentation, main therapeutics and long-term outcomes.

Methods {#Sec4}
-------

Genomic DNA was isolated from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Courtaboeuf, France). Eleven exons, including all intron--exon boundaries, were amplified from genomic DNA by means of PCR with specific intron-flanking primer pairs. Patients 1--20 and patient 30 were diagnosed at Necker Enfants-Malades Hospital in Paris and patient 21--29 were diagnosed in the university hospital in Grenoble as already described^[@CR5]^.

For flow cytometry determination of Tregs, PBMCs were membrane stained with anti-CD4 and anti-CD25 monoclonal antibodies and then fixed, permeabilized, and stained with Alexa Fluor 488 anti-human FOXP3 monoclonal antibodies (used for patients 2, 4, 8, 14, 25 and 26) or allophycocyanin-labelled anti-human FOXP3 as described by Moes et al.^[@CR6]^.

Consequences of mutations on protein function were predicted using three algorithms: Polyphen2, Sift (Sorting Intolerant From Tolerant, J. Craig Venter Institute) and Mutation Taster ([www.mutationtaster.org](http://www.mutationtaster.org)). Mutations were next ranked on the basis of the predicted impact of each variant by combined annotation-dependent depletion (CADD), and compared with the mutation significance cutoff (MSC), a gene-level specific cutoff for CADD scores (<http://pec630.rockefeller.edu:8080/MSC/>).

We compared the survival of patients with forkhead domain-affecting and other *FOXP3* mutations for whom sufficient data were available using the Gehan's generalised Wilcoxon test. This included patients who underwent HSCT or died in utero. We also employed Fisher's test to investigate the proportions of patients surviving beyond the age of three years (the median of follow-up) depending on the presence or absence of this type of mutation (two-tailed *p* value reported). The age at onset in the two groups was compared using the Mann--Whitney *U* test. The alpha level was set at 0.05. Statistical analyses were performed using Statistica 12 (StatSoft Inc., Tulsa, USA).

Results {#Sec5}
=======

Demographic Data {#Sec6}
----------------

Twenty-seven male infants, two brothers who died in utero (in the 19th and 24th week of gestation) and one preterm neonate (32nd week of gestation) from 26 families were included in this study (Table [1](#Tab1){ref-type="table"}). None of the families were consanguineous. Nineteen patients have been previously described in cohort studies or as case reports^[@CR5]--[@CR14]^. The median age at disease onset was 1.5 month \[first to third quartile; 0--84\]. The median duration of follow-up was 4 years \[0--22\] and the average of age at last follow-up was 7.6 years.Table 1Characteristics of the French IPEX cohortPtsMutationCADDAge at onsetDiarDiabEczOtherAIE-75 kDaAuto-immunityTherapyComplicationsFollow-upReported by1g.−6247\_−4859delGAG3 wk+−+Allergy (food), cheilitis and sepsis+AEAPN, Ctc, Aza, Rapa, FK506 Infliximab and HSCTTM with ESRF pulmonary infection, acute pancreatitis, and osteopeniaDeath 10.5 y6, 102g.−6247\_−4859delGAG5 wk+−+Allergy (food), cheilitis, sepsis and HP gastritis+AEACtc, Aza, Rapa, Cyclo and FK506Pulmonary adenoviral infection, BPNP and BDAlive 14.5 y6, 103c.751_753 delGAG4 wk+++AHA, agranulocytosis and hepatitis+AEA, ANA, anti-islet, SMA, Coombs, anti-PNN and anti-GADPN, Ctc, Aza, FK506 and RituximabAHA, Pseudomonas infection and BDDeath 8 mo6, 114c.751_753 delGAG6 wk+−+Hypothyroidism, interstitial nephritis and AHA+AEAPN, Ctc, Aza, MTX, FK506, Rapa, Rituximab and HSCTRectal abscess, colostomy, cholangitis, EBV reactivation, BD, VZV infection, intracranial haemorrhage, cataract and bones fractureAlive 17 y6, 115c.736 − 1G \> C247 wk+++Allergy (food)−ANA, anti-insulin and anti-GADPN and RapaPulmonary infection and BDAlive 5 y6c.816 + 5G \> A114 wk++++AEA, anti-insulin and anti-enterocytePN, Ctc, Aza, Rapa and FK506PNP and VZV infection wt hepatitisAlive 14 y67c.1121T \> G274 wk+−+AHA, thrombocytopenia and allergy+naCtc, Aza, FK506 and RapaDeath during HSCT induction therapyDeath 14 mo6, 10, 118c.1113T \> G234 wk+++Anaemia−ANA and anti-GADPN, Ctc, FK506 and HSCTDeath 3 y89c.210delG6 wk+−++naPN, Ctc, FK506 and HSCTDeath 1.5 y10c.1015C \> G241 wk+++AHA+AEAFK506SepticaemiaDeath 7 mo1111c.1100T \> G273 mo+++Tubulointerstitial nephritis+AEA, ANA, anti-GAD and anti-mitochCts, Cyclo and ALSDeath 2 y1012c.751_753 delGAG271 wk+++Membranous glomerulonephritisnaAEA, ANA, SMA and anti-keratinCts, Cyclo and ALSRecurrent infections (*S. hominis*. *S, epidermidis*)Na613c.736 − 1G \> A248 wk+++Anaemia, thrombocytopenia and membranous glomerulonephritisnaAEA, ANA, anti-GAD, anti-mitoch and anti-plateletCtc, Cyclo and ALSRecurrent infections (*S. epidermidis*, *S. aureus*)Na614c.152G \> A2010 mo+−−+cANCA, ANA and anti-colonocyte5-ASA, Ctc, Aza and FK506/Alive 4.5 y15c.−23 + 1G \> A248 wk+−+Allergy (food++), anaemia and thrombocytosis−PNFood allergyAlive 3.3 y16c.817A \> C57 y+−++AEARapaInterstitial nephritis secondary to CycloAlive 10 y917c.1091A \> G2624 days+−+Allergy (food)+PN, Aza and FK506Alive 19 y18c.264delC5 y++−Tubulo-interstitial nephritis, allergy (food)+Anti-GADRenal transplantation, Ctc, Rapa, MFM, FK506, ALS and HSTDiabetes under Ctc. exocrine pancreatitis, CMV and EBV reactivation, TM, Pseudomonas infection and digestive GvHDDeath 7.3 y19c.1157G \> A344 wk+−+HMG with severe hepatitis, thrombocytopeniananaCtc, Rapa IV and AlemtuzumabCMV infection and MRSA infectionDeath 7 mo20c.1010G \> A334 wk++−Respiratory failure+Anti-GADPN, Rapa, Ins, noninvasive ventilation and HSCTTMAlive 1 y21c.227delT3 wk+−+Autoimmune hepatitis and membranous glomerulonephritis+Anti-actin, anti-TPO, ANA and AEAPN, Ctc, Cyclo and AzaMultiple flare-ups. and steroid-induced osteopeniaAlive 22 y7, 1222c.227delT2 wk+−+nanaPNDeath 6 wk723c.816 +4A \> G78 wk+−+Cow's milk protein allergy, asthma, SA and tubulointerstitial nephritis+Anti-actinPN, Ctc, Cyclo and AzaSepticaemia (*E. coli*)Death 3 y524c.−23 + 5G \> A123 wk+++Arthritis+Anti-thyroglobulin, ASCA and ANCAPN and InsAlive 5 y25c.-23 + 5G \> A1213 mo++++ASCA, anti-islet cell, anti-GAD and anti-TGPN, Ins and Gluten evictionCoeliac diseaseAlive 3 y26c.1189C \> T33Birth+−+nanaPNSepticaemia (*E. coli*)Death day 427c.1033C \> T24IU−−−nana−IFD1328c.1033C \> T24IU−−−nana−IFD1329c.751_753 delGAG2 mo+−+Hypothyroidism+Anti-pancreas (exocrine) and anti-thyroglobulinRapa, Ctc and PN*S. haemolyticus* sepsisAlive 3 y30c.1015C \> T254 wk+−+Cow's milk protein allergy+AEA, ANA, anti-GAD, ANCA and anti-plateletPN, Rapa IV, Ctc, Ruxo, Rituximab and HSCTPneumopathy complicated by septicaemia (*P. aeruginosa*)Alive 6 mo*AEA* anti-enterocyte antibodies; *AHA* autoimmune haemolytic anaemia; *ALS* antilymphocyte serum; *ANA* antinuclear antibodies; *ANCA* antineutrophil cytoplasmic antibodies; *ASCA* anti-*Saccharomyces cerevisiae* antibodies; *anti-GAD* anti-glutamic acid decarboxylase antibodies; *anti-mitoch.* anti-mitochondria antibodies; *anti-TG* anti-transglutaminase antibodies; *anti-TPO* anti-thyroperoxidase antibody; *AZA* azathioprine; *BD* bronchial dilatation; *CADD* combined annotation-dependent depletion; *Ctc* corticoids; *Cyclo* cyclosporine; *Diar* diarrhoea; *Diab* diabetes; *Ecz* eczema; *ESRF* end-stage renal failure; *GvHD* graft versus host disease; *HMG* hepatomegaly; *HP* *Helicobacter pylori*; *HSCT* hematopoietic stem cell transplantation; *IFD* intrauterine foetal death; *Ins* insulin; *IV* intravenous; *MFM* mycophenolate mofetil; *mo* month; *MRSA* methicillin-resistant *Staphylococcus aureus*; *MTX* methotrexate; *na* not available; *PN* parenteral nutrition; *Rapa* rapamycin; *Ruxo* ruxolitinib; *SMA* smooth muscle antibodies; *TM* thrombotic microangiopathies; *wk* week; *y* year.

Clinical and Biological Data {#Sec7}
----------------------------

Chronic diarrhoea was the most frequent symptom: it was the initial symptom in 18 patients (68%) and was present in 28 patients (100%) during the course of the disease (Table [1](#Tab1){ref-type="table"}). Skin lesions were mainly eczematous and were associated with diarrhoea in 22 patients (78%). Erythroderma was the first and main symptom in patients (pts) 7 and 26. In seven patients, the first clinical manifestation was T1D, at a median age of 1.5 months \[0--13 months\]. Twelve patients (43%) developed T1D during the course of the disease. Nine of them (75%) had positive anti-glutamic acid decarboxylase or anti-islet antibodies.

Ten patients (35%) developed severe food allergy. The main incriminated food antigen was cow's milk protein, with presence of specific IgE in all tested patients. Among these patients, pt15 presented at the age of 2 months with severe diarrhoea associated with cow's milk protein allergy. Although diarrhoea resolved spontaneously, his food allergy extended to eggs, exotic fruits, nuts, soy, beef and veal without any other intestinal or extra-intestinal symptoms.

Haematological disorders occurred in eight patients (29%), six had anaemia (positive Coomb's test *n* = 4), three had thrombocytopenia (anti-platelet antibodies *n* = 2) and one had neutropenia with antineutrophil antibodies.

Eight patients (25%) developed nephropathy (median age 3 years \[1.8--9\]). Interstitial nephropathy was described in five cases (pts 4, 11, 16, 18 and 23) among them, in three most probably linked to cyclosporine medication (pts 11, 16 and 23). Three patients presented glomerulonephritis linked to the disease (pts 12, 13 and 21). Chronic nephritis was the initial manifestation in pt 18; it led to chronic renal failure that required peritoneal dialysis at the age of five followed by kidney transplantation at the age of six.

Four (14%) patients developed hepatitis, with presence of anti-smooth muscle autoantibodies in two cases (pts 3 and 21). One case of hepatitis occurred during mercaptopurine therapy (pt 17).

Twenty-one out of 23 tested patients (91%) had markedly elevated IgE, ranging between 94 and 12,000 kUI/L (*N* \< 40 kUI/l). Autoantibodies to AIE 75 kDa, directed against harmonin, a brush border protein^[@CR15]^, were found in 22 out of the 23 tested patients (95%). Twenty patients showed positive auto-antibodies against various targets (summarised in Table [1](#Tab1){ref-type="table"}). Among them, 13 patients showed positive anti-enterocyte antibodies. No auto-antibody was detected in two patients (pts 15 and 17). Peripheral Tregs were analysed in ten subjects. In three children (pts 1, 2 and 3), CD4^+^CD25^+^FOXP3^+^ Tregs represented less than 1% of peripheral CD4^+^ T (normal range: 5--10%). Patients 8, 10 and 21 had reduced levels 3.0%, 3.3% and 1.5%, respectively. In contrast, Tregs numbers were normal in pts 7 (8.0%), 24 (7.5%), 25 (11.0%) and 30 (7.5%), while the mean of fluorescence was decreased in pt 25 (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Evaluation of regulatory T cells frequency in an atypical IPEX case.**a** Flow cytometry on isolated PBMCs from patient 25 and a healthy control subject after membrane staining with CD3 and CD4 and intracellular staining of FOXP3. **b** Mean fluorescence intensity of FOXP3 in CD3^+^CD4^+^ cells in control and patient 25

Three patients with atypical phenotypes were included (pts 15, 24 and 25). Patients 15 and 24 presented severe diarrhoea early in their life, which resolved without immunosuppressive therapy. One is now 4-year-old with a severe food allergy and the second has T1D. Pt 25, a cousin of pt 24 presented with late onset diabetes at the age of 13 months without gastro-intestinal tract involvement. He later developed a "coeliac-like" disease with positive anti-transglutaminase antibody and severe villous atrophy. Despite high AIE-75 kDa, hypereosinophilia and elevated total IgE pts 24 and 25 had a normal frequency of Tregs (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Histological analysis of neonatal IPEX form.**a** Standard autopsy picture of patient 26, showing diffuse skin erythema and **b** haematoxylin--eosin standard staining of an intestinal biopsy showing mononuclear infiltrate of the intestinal chorion

Endoscopic and histological data {#Sec8}
--------------------------------

Nineteen patients underwent at least one endoscopic procedure during the course of the disease. Six patients presented only inflammation in the upper gastro-intestinal tract with pale and fragile mucosa (pts 3, 6, 7, 8, 9 and 23). Patient 25 presented severe duodenal villous atrophy associated with high level of anti-transglutaminase. Seven patients had a combination of upper gastrointestinal and colon inflammation with severe inflammation and ulcerations at onset of symptoms (pts 1, 2, 4, 16, 19, 21 and 24). Patient 14 displayed only colitis and pt29 an ileocolitis. Endoscopy showed normal mucosa in pt5 despite severe diarrhoea, for pt18, who was under immunosuppressive therapy in the context of a pre-transplant work-up. Also, no macroscopic inflammation was reported for pt15 during a classical evaluation of the disease course.

Duodenal biopsies showed polymorphic infiltration of the lamina propria with lymphocytes, macrophages, plasmocytes and eosinophils. Histologic analysis of the lower part of the gut (colon sigmoid and rectum) highlighted an inflammatory infiltrate of the lamina propria with a predominance of lymphocytes and eosinophils.

Autopsy of pt26, who died in the neonatal period, showed CD3^+^CD4^+^ lymphocytic inflammatory infiltrates of the skin, the digestive tract, the pancreas and of the liver as well (Fig. [2](#Fig2){ref-type="fig"}).

*FOXP3* mutations {#Sec9}
-----------------

Molecular diagnosis was obtained by targeted Sanger sequencing. Median age at molecular diagnosis was 5 years \[0.25--8\] and 4 years for patients born after 2001 (the discovery of *FOXP3* as disease causing mutation).

As shown in Fig. [3](#Fig3){ref-type="fig"}, 22 germinal mutations were identified in our cohort. Amongst these variants, four novel missense mutations were identified: c.−23 + 1G \> A (pt 15), c.−23 + 5G \> A (pts 24 and 25) c.1015C \> T (pt30), c.1091A \> G (pt17) and one nucleotide deletion mutation c.264delC (pt18), which resulted in a frameshift and introduced a premature stop codon. The first two variants were designated as splice-altering by in silico splicing defect predictions tools while they were all absent from the Exome Aggregation Consortium (ExAC) database. Of note, the CADD of c.−23 + 1G \> A (24), c.−23 + 5G \> A (12), c.1015C \> T (25) and c.1091A \> G (26) were well above the MSC of FOXP3 (0.002) (Table [1](#Tab1){ref-type="table"}).Fig. 3*FOXP3* mutations in the cohort.Schematic representation of the *FOXP3* gene with all the mutations found in our IPEX patients indicated

Treatment and outcome {#Sec10}
---------------------

The mean follow-up was 5 years (range: 0--22), two patients were lost to follow-up, and 10-year survival was 43% (Fig. [4a](#Fig4){ref-type="fig"}). Twenty-three patients received steroids. During the course of the disease, 13 patients took azathioprine and 2 were treated with mycophenolate mofetil. Five patients died during the first year of life due to multiorgan failure caused by severe diarrhoea (pts 3, 7, 10, 19, 22 and 25), at a median age of 5 months (0--9). Three patients died during a flare-up of their disease or due to *Escherichia coli* septicaemia and multiple organ failure (pts 9, 11 and 23). Three patients improved on tacrolimus (pts 6, 14 and 16) and four on sirolimus medication (pts 2, 5, 20 and 30). Among them two were also receiving azathioprine (pts 2 and 6). One patient was treated by cyclosporine, mycophenolate mofetil and steroids (pt 21). Three patients never received immunosuppressive therapy (pts 15, 24 and 25).Fig. 4**a** Survival of IPEX patients in the French cohort. **b** Kaplan--Meier curves illustrating the poorer survival of IPEX patients harbouring forkhead (FKH) domain-affecting *FOXP3* mutations as compared with other mutations

Seven patients underwent HSCT at a mean age of 5.5 years (range: 0.5--12.8) (Table [2](#Tab2){ref-type="table"}). Two patients were transplanted with a matched sibling donor, three patients (pts 9, 18 and 30) with a mismatched related donor and two patients (pts 1 and 20) with a matched unrelated donor. Conditioning regimens (CR) are given in Table [2](#Tab2){ref-type="table"}. Five patients displayed full engraftment, one patient transplanted with a non-myeloablative CR showed mixed chimerism, while one patient (pt9) failed to engraft. Four patients died after HSCT, due to graft-versus-host disease and transplant-related toxicities (microangiopathies and renal failure) (*n* = 2), graft rejection (*n* = 1) or hemophagocytosis at 30 months post-transplant (pt8).Table 2Outcomes in IPEX patients treated by hematopoietic stem cell transplantationPtAge at onsetAge at BMTMutationConditionningDonorGvH preventionRemission after transplantationGvHDComplication post after transplantationOutcome11 mo10.5g.-6247\_-4859 delGAGFlu, ALM and Bu (RIC)MUDSteroids/MMF/Acute grade IIMicroangiopathies and renal failureDeath 10.5 y41.5 mo12.8c.751_753 delGAGFlu, ALM and Bu (RIC)MSDCY/MMFYesAbsenceAlive 17 y81 mo0.5c.1113T \> GATG, CY and Bu (MAC)MSDCY IVYesAbsenceHemophagocytosisDeath 3 y91.5 mo1c.210delGATG, BU and CY (MAC)MMRDCY/MMF/AbsenceGraft rejectionDeath 1.5 y185 y7c.264delCflu, Cx, TBI 2GY and post CY (NMA)MMRDCY/MMF/Grade IIIMicroangiopathies and renal failureDeath 7.3 y201 mo1c.1010G \> Aflu, Bu and ALMMUDCY/MMFYesGrade IIIAlive 2 y301 mo5.5c.1015C \> TRitu, ALM, Bu, Flu and post CY (MAC)MMRDCY/MMFYesChronicAlive 1.5 y*ALM* alemtuzumab; *ATG* anti-thymoglobulin; *Bu* busulfan; *CY* cyclophosphamide; *post CY* post-transplant cyclophosphamide; *BM* bone marrow; *Flu* fludarabine; *RIC* reduced intensity conditioning; *MAC* myeloablative conditioning; *NMA* non myeloablative conditioning; *GvHD* graft-versus-host disease; *Melph* melphalan; *mo* month; *MSD* matched sibling donor; *MUD* matched unrelated donor; *MMRD*: mis-matched related donor, *Pts* patients; *TBI* total body irradiation; *y* year, *MMF* mycophenolate mofetil; *TM* thrombotic microangiopathies; *ESRF* end-stage renal failure

The survival of children harbouring forkhead domain-affecting mutations (both missense and frameshift; *n* = 15) was poorer than that of children with other mutations (*n* = 14; *p* = 0.002; Fig. [4b](#Fig4){ref-type="fig"}). Amongst the 12 patients who died before the age of three, 10 harboured a forkhead domain-affecting mutation (83.3%) (*p* = 0.005). Only three patients with a similar mutation survived beyond the age of three years (23.1%) (*p* = 0.005). The age at onset of the disease did not differ between the two groups (*p* = 0.14).

Discussion {#Sec11}
==========

Our national multicentre cohort of 30 IPEX patients unravels an enlarged clinical spectrum of IPEX with atypical phenotypes, and mild evolutions in some patients even without therapy. These observations are particularly important when defining the most appropriate treatment strategy while looking for genetic prognostic factor.

In 2012, Barzaghi et al. comprehensively reviewed all 136 cases described in the previous 12 years with the aim to define the clinical features of the syndrome^[@CR16]^. The major elements of the clinical picture were: diarrhoea, T1D, and skin involvement. In our study the prevalence of all three main symptoms was in keeping (less than 15% difference) with this previous report^[@CR16]^. Diarrhoea was the leading manifestation, present in 100% of patients and often life-threatening. Eczematous skin lesions concerned nearly three-quarters of cases. Almost half of the children had T1D; in most of them it was the first manifestation of IPEX. One in five subjects had renal disorders. Of particular interest, we observed a large percentage of food allergic patients in our cohort, 35% compared to 11% in the previous report. We suggest that because of a high rate of allergic symptoms, clinicians should carefully consider the introduction of complementary foods in IPEX patients.

Our study described several unusual phenotypes. Patient 18 presented first with renal tubulo-interstitial nephritis, which required renal transplantation and he developed classical severe diarrhoea only 1 year after organ transplant. A 7-month-old baby boy who exhibited a glomerulonephritis in the absence of any digestive problems was also previously reported, suggesting indeed that renal disorder could be the first manifestation of the disease^[@CR17]^. Mutations in the FKH domain interfere with nuclear import and DNA binding, both of which are critical for FOXP3 repressor activity. These latter mutations may also be associated with more attenuated phenotypes.

Our cohort includes three patients with atypical phenotypes (pts 15, 24, and 25). Despite severe diarrhoea early in life, none of them needed immunosuppressive therapy. Two novel mutations were identified in the three patients: c.−23 + 1G \> A and c.−23 + 5G \> A. Interestingly, in pt 25 a decreased FOXP3 expression was observed on CD3^+^CD4^+^FOXP3^+^ cells compared to control despite normal frequency of Tregs (Fig. [1](#Fig1){ref-type="fig"}). All three patients (15, 24 and 25) carry intronic mutations located within the first splice donor site. Mutations outside *FOXP3* coding regions, within an intron/exon splice junction or in the first polyadenylation signal of the gene, may interfere with normal gene expression and protein production. Moreover, it has been shown the first splice donor site is highly methylated due to the presence of multiple conserved noncoding enhancer sequences, responsible of epigenetic regulation^[@CR18]^. As they are both hypomorphic mutations, we speculate that variants in this particular region might affect the overall methylation status leading to a decreased FOXP3 expression and resulting in an atypical phenotype.

We also report a new IPEX case of a preterm infant with severe erythroderma (pt26) who died of septicaemia at day four of life. Although autoimmune diseases in utero are very rare, the number of reported neonatal cases of IPEX has been increasing since the first description in 2015 (13). Foetal and neonatal forms of IPEX indicate that the disease could start in utero, which suggests that Tregs are important for foetal tolerance.

A large variety of autoantibodies are described in IPEX. Anti-harmonin (anti-AIE75 kDa) is the most specific antibody in IPEX-patients, even though it has also been described in CD25 deficiency^[@CR15]^. Totally, 90% of patients described herein had a positive anti-AIE75 kDa serology. Therefore, we find it to be a useful tool for the preliminary screening of patients that may possibly distinguish between IPEX syndrome and other immune deficiencies, such as autoimmune polyendocrinopathy--candidiasis--ectodermal dystrophy^[@CR19]^. In our experience, severity and evolution of the disease do not correlate with the titre of anti-AIE75 kDa. In four of our patients who previously had positive anti-AIE75 kDa titres the antibodies have become undetectable under therapy. Indeed, it was shown that anti-AIE75 kDa in IPEX patients become undetectable or persist at low titres in remission after immunosuppressive therapy or HSCT^[@CR20]^.

The largest yet still homogenous group of pathogenic variants that we could identify were mutations affecting the forkhead domain of *FOXP3*. In our cohort, the survival of patients with variants of this type was markedly poorer and rarely exceeded three years. This highlights its potential use as a genetic prognostic factor in IPEX. Our exploratory search for associations between phenotypic traits and forkhead domain-affecting *FOXP3* mutations yielded negative results. The lack of genotype--phenotype correlation may reflect the complex intracellular interactions of FOXP3, and strongly suggests the role of epigenetic regulation in determining the clinical picture and outcome (18). The range of manifestations and severity can also vary between patients with the same mutation, suggesting that modifier loci in the genetic background, as HLA haplotype and the lymphocyte repertoires, and/or environmental exposures modify the course of disease.

Lack of Tregs lead indirectly to a deregulation of T effector with an enrichment of T helper type 2 cells, an over production of IL-17 cytokines and a deregulation of autoreactive B cells (21). This balance between regulatory cells and effector cells could change from a patient to another.

The two main treatment modalities for IPEX syndrome are chronic immunosuppression and hematopoietic stem cell transplantation. Immunosuppressive therapy has to be introduced as soon as possible in order to limit any further damage. In our study, 25 patients received steroids, which appear to be the most efficacious first-line pharmacotherapy, then followed by other immunosuppressive agents for long-term therapy. As observed in this series, combination of at least two immunosuppressive drugs is needed to control the disease. In our cohort, only two patients improved on tacrolimus alone and three on sirolimus alone. We made a greater use of azathioprine with tacrolimus compared with previous reports, where mycophenolate mofetil was a common choice. Classically, a top-down approach with initial steroids and sirolimus is advised (approx. 0.15 mg/kg/day), adjusted to maintain serum sirolimus levels between 8 and 12 ng/mL^[@CR21]^. In the majority of cases, chronic immunosuppression is partially effective, and increases the risks of severe and/or opportunistic infections.

HSCT is currently the only curative therapy for IPEX. HSCT was initially proposed after multiple relapses and when combination immunosuppressive therapy had been tried and failed. Early HSCT seems to lead to better outcomes. Fifteen IPEX patients treated by HSCT were described so far in the literature. Most of them (10/15) received the transplant in their first two years of life with a large survival rate (90%). A recent study by Nademi et al.^[@CR22]^ also supports this observation: of five infants who had HSCT in the first year of life (two at six months and three at ten months) all patients survived. In our patients the median age at HSCT was 5.5 (range: 0.5--12.8) years.

In conclusion, IPEX is phenotypically heterogeneous ranging from severe intrauterine forms to moderate phenotypes with atypical course of the disease which do not require extensive immunosuppressive treatment. Early *FOXP3* sequencing facilitates rapid diagnosis, which is necessary since it permits aggressive, combined immunosuppressive therapy and opens the way to early HSCT.

Study Highlights {#Sec15}
================

What is current knowledge? {#Sec150}
--------------------------

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is an autoimmune genetic disorder.Main clinical features include severe refractory enteropathy, type 1 diabetes and dermatitis.Hematopoietic stem cell transplantation is the only known curative treatment.

What is new here? {#Sec360}
-----------------

*FOXP3* mutations localised in the first intron can produce atypical, attenuated phenotypes.Mutations affecting the forkhead domain are associated with poor survival.Five new FOXP3 mutations leading to IPEX phenotype are identified: c.−23 + 1 G \> A, c.−23 + 5G \> A, c.264delC, c.1015C \> T and c.1091A \> G.Immunosuppressive therapy may yield excellent results in selected patients.
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